RISPERDAL
RISPERIDONE
Approval overview RISPERDAL is listed in Drugs@FDA under application 021444 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient RISPERIDONE Form and strength TABLET, ORALLY DISINTEGRATING;ORAL - 0.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor JANSSEN PHARMS Submission history Latest submission status date: 2025-01-22 00:00:00.
Structured Monograph
Clinical summary
Approval overview RISPERDAL is listed in Drugs@FDA under application 021444 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient RISPERIDONE Form and strength TABLET, ORALLY DISINTEGRATING;ORAL - 0.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor JANSSEN PHARMS Submission history Latest submission status date: 2025-01-22 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.